Loading...
XSHG
688513
, Last price  
Name

Chengdu Easton Biopharmaceuticals Co Ltd

Chart & performance

D1W1MN
XSHG:688513 chart
P/E
—
P/S
—
EPS
2.37
Vol. 1Y
—
Shs. 5Y
3.38%
Rev. 5Y
7.63%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.33b
-1.36%
162,499,917208,744,068240,717,890338,801,753476,337,981768,758,600947,235,160921,918,4731,022,935,5871,170,512,8991,117,120,7481,349,755,3021,331,390,248
Net income
284m
+19.24%
14,731,31129,232,70437,619,16857,316,55964,365,628135,020,131108,611,581178,161,837232,427,618246,520,759226,574,425238,234,169284,059,384
CFO
265m
+0.65%
28,117,36946,712,07246,712,07250,566,741106,057,81385,699,816166,787,530141,830,211156,524,544147,596,571151,944,665275,252,239263,240,369264,941,204
Dividend
Jun 02, 20260.49 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chengdu Easton Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the full spectrum of drug development, encompassing research, development, production, and market distribution of medicinal products. The company offers finished medications tailored for various medical disciplines, including pain management (anesthetics/analgesics), cardiovascular health, oncology, and pediatrics. Beyond ready-to-use drugs, it also manufactures active pharmaceutical ingredients (APIs) for a broader range of therapeutic areas, such as cancer treatment, heart conditions, pain relief, anti-inflammatory uses, gastrointestinal issues, antiemetics, neurological and psychiatric disorders, and urinary system ailments. Established in 2009, the firm is headquartered in Chengdu, China.
IPO date
Sep 02, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT